Parkinson's Disease Trial, Recruiting NCT06485986 Sponsor: University of Oxford Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT06485986
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their informed consent to take part in the study.
  • People aged 18 years or older, of any gender.
  • People who have been diagnosed with Parkinson's disease and have had a deep brain stimulation (DBS) device surgically implanted in a specific brain region, in addition to taking medication to replace dopamine.
  • People who have been diagnosed with Parkinson's disease, either with or without impulse control disorders (such as difficulty controlling urges or behaviours) since their Parkinson's diagnosis — both groups may be considered.
  • People who are willing and able to sit in a MEG brain scanning machine and follow instructions during the study.
  • People who are willing and able to delay taking their morning Parkinson's medication for up to four hours on the day of the study (to allow around 180 minutes of testing time plus travel).

Who may not be able to join:

  • People who have a significant language barrier that prevents them from understanding the study's purpose or instructions, even with the help of an interpreter.
  • People who have other implanted medical devices in their body that could interfere with the MEG brain scan recordings.
  • People who have a history of other neurological conditions (brain or nervous system disorders) separate from Parkinson's disease.
  • People who are already enrolled in another clinical trial related to a neurological condition, including Parkinson's disease, that could affect the results of this study.
  • People who are unable to sit still in a MEG scanner for the full duration of the study — for example, due to chronic pain or joint conditions such as osteoarthritis. A treating clinician would assess this (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 01865222763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2024
Est. completion
1 August 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Identify effect of therapeutic STN-DBS on frontosubthalamic networks in PD related ICDs during decision making and impulse control

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov